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Abstract: Indole derivatives including bromoindoles have been isolated from the South 
Pacific  marine  sponges  Rhopaloeides  odorabile  and  Hyrtios  sp.  Their  structures  were 
established through analysis of mass spectra and  1D and 2D NMR spectroscopic data. 
Their potential inhibitory  phospholipase A2 (PLA2), antioxidant and cytotoxic activities 
were evaluated. The new derivative 5,6-dibromo-L-hypaphorine (9) isolated from Hyrtios 
sp. revealed a weak bee venom PLA2 inhibition (IC50 0.2 mM) and a significant antioxidant 
activity  with  an  Oxygen  Radical  Absorbance  Capacity  (ORAC)  value  of  0.22.  The 
sesquiterpene aureol (4), also isolated from Hyrtios sp., showed the most potent antioxidant 
activity with an ORAC value of 0.29.  
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1. Introduction 
A  great  variety  of  simple  and  substituted  indole  derivatives,  including  halogenated  indoles, 
bisindoles  and  tryptamine  derivatives,  have  been  previously  isolated  from  marine  organisms  [1]. 
Indole  derivatives  are  known  to  display  various  bioactivities  such  as  anticancer,  antibiotic,  and  
anti-inflammatory activities [2]. Antioxidant activities were also recently reported for some analogues 
such  as  2,2-diphenyl-1-picrylhydrazyl  (DPPH)  radical  scavengers,  highlighting  an  additional 
bioactivity in the series [3]. 
In our ongoing search for bioactive compounds within the frame of the CRISP program (Coral Reef 
Initiative  in  the  South  Pacific),  the  crude  extracts  of  two  South  Pacific  marine  sponges  were 
investigated, based on their significant anti-PLA2 activities. One specimen of Rhopaloeides odorabile 
was  collected  from  the  Solomon  Islands  and  one  specimen  of  Hyrtios  sp.  from  the  Fiji  Islands. 
Fractionation of each of the crude extracts led to the isolation of a series of indole derivatives.  
Three  known  monomeric  indoles  were  isolated  from  the  marine  sponge  R.  odorabile  and  five 
dibromoindole derivatives, including the new derivative, 5,6-dibromo-L-hypaphorine (9), in addition to 
the sesquiterpene aureol (4) were obtained from the sponge Hyrtios sp.  
The current report describes the isolation of alkaloids 1–9 and structural identification of the new 
analogue, 5,6-dibromo-L-hypaphorine (9). Anti-PLA2, antioxidant and cytotoxic activities of the series 
were evaluated and are presented. 
2. Results and Discussion 
2.1. Isolation of Indole Derivatives 
Successive chromatographic fractionation of the CH2Cl2 extract of R. odorabile using silica gel 
column  chromatography  and  purification  of  the  anti-PLA2  fractions  on  C18  HPLC  afforded  three 
known  monoindole  alkaloids  (1H-indol-3-yl)  oxoacetamide  (1)  and  (1H-indol-3-yl)  oxoacetic  acid 
methyl ester (2), both previously isolated from the marine sponge Spongosorites sp. collected off the 
coast  of  Jeju  Island,  Korea  [4]  and  6-bromoindole-3-carbaldehyde  (3)  from  the  marine  sponge 
Pseudosuberites hyalinus [5] (Figure 1). 
Chromatographic fractionation of the CH2Cl2 extract of Hyrtios sp. using silica gel afforded aureol 
(4), rapidly identified by comparison with literature data [6]. Chromatographic fractionation of the 
MeOH extract of Hyrtios sp. using C18 and LH 20 columns followed by successive ODS C18 HPLC 
revealed  the  presence  of  five  dibromoalkaloids  5–9.  The  structures  of  the  known  compounds  
5–8 were rapidly determined as 5,6-dibromotryptamine 5, N-methyl-5,6-dibromotryptamine (6) [7], 
N,N-dimethyl-5,6-dibromotryptamine  (7)  [8],  and  5,6-dibromoabrine  (8)  [9]  by  comparison  with 
literature  data.  The  structure  of  the  new  metabolite,  5,6-dibromo-L-hypaphorine  (9),  was  obtained Mar. Drugs 2011, 9                       
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through  detailed  examination  of  mass  spectrometric  data  and  extensive  1D  and  2D  NMR  studies 
(Figure 2).  
Figure  1.  Structures  of  indole  derivatives  1–3  isolated  from  the  marine  sponge 
Rhopaloeides odorabile  
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Figure 2. Structures of compounds 4–9 isolated from the marine sponge Hyrtios sp. 
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2.2. Structure Elucidation of 5,6-Dibromo-L-hypaphorine (9) 
Compound  9  was  isolated  as  an  optically  active  pale  yellow  oil,  with  []
20
D  +28  (c  0.06,  
MeOH–1 N HCl, 8:2). The positive mode ESI mass spectrum of 9 showed a 1:2:1 molecular ion 
cluster  at  m/z  402.9,  404.9,  406.9,  characteristic  of  the  presence  of  two  bromine  atoms  and 
corresponding to the molecular formula C14H17N2O2
79Br2 for the pseudomolecular ion [M + H]
+ at  
m/z  402.9667. 
1H  and 
13C  NMR  data  for  9  in  DMSO-d6  were  similar  to  those  reported  for  
5,6-dibromoabrine (8), in particular the resonances of three singlet protons in the aromatic region at H 
8.02 (1H, s), 7.72 (1H, s), 7.27 (1H, s), a methine proton at H 3.67 (1H, dd, J = 10.1, 3.3), methylene 
protons at  H 3.21 (2H, m) and the presence of a carboxylate function  at  C 167.0 (C). The main 
difference between 8 and 9 was the presence of a N
+Me3
 cation, indicated by a nine-proton singlet in 
the 
1H NMR spectrum of 9 at  3.17 (9H, s). In addition, two broad singlet protons at H 11.20 (1H, 
brs)  and  8.45  (1H,  brs)  suggested  the  presence  of  an  amine  and  hydroxyl  function,  respectively. 
Furthermore, COSY correlations between the methine proton at H 3.67 with methylene protons at  
H 3.21 and between the amine proton at H 11.20 with proton at H 7.27 indicated the presence of a  
CH2-CH group and a NH-CH group, respectively. Five non-protonated aromatic carbons at C 135.7 
(C-7a), 128.2 (C-3a), 114.8 (C-6), 112.6 (C-5) and 109.5 (C-3) suggested 5,6 dibromosubstitution of 
the indole nucleus, which was supported by the observed HMBC correlations as presented in Table 1 Mar. Drugs 2011, 9                       
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and  by  comparison  with  literature  values  for  8  [9].  Thus,  the  new  alkaloid,  was  identified  as  
5,6-dibromo-L-hypaphorine  (9),  a  new  member  of  the  hypaphorine  family.  Halogenation  on  the 
benzene ring of tryptophan derivatives does not affect the sign of optical rotation [10], therefore 9 was 
assigned  as  L-configuration  (9S)  by  comparison  of  its  optical  rotation  value,  []
20
D  +28  (c  0.06, 
MeOH–1 N HCl, 8:2), with those reported in the literature for 6-bromo-D ([]
17
D −27 (c 0.8, MeOH, 
TFA, 8:1)) [11] and L-hypaphorine ([]
15
D +58 (c unspecified, MeOH, TFA, 8:1)) [12].  
Table 1. NMR spectroscopic data of 5,6-dibromo-L-hypaphorine (9)
a. 
no. 
1H 
13C  HMBC
b 
1-NH  11.20 brs  -  2, 3 
2  7.27 s  126.8  3, 3a, 7a 
3    109.5   
3a    128.2   
4  8.02 s  123.1  3, 5, 6, 7a 
5    112.6 
c   
6    114.8 
c   
7  7.72 s  116.0  3a, 5, 6, 7a 
7a    135.7   
8  3.21 m  24.2  2, 3, 3a, 9, 10 
9  3.67 dd (10.1, 3.3)  78.2  3, 8, 10 
10    167.0   
OH  8.45 brs    10 
N(CH3)3  3.17 s  51.0   
a  Measured in DMSO-d6 at 400 MHz for 
1H and 75.15 MHz for 
13C, J in Hz; 
b  HMBC correlations optimized for 7 Hz, are from proton(s) stated to the indicated carbon; 
c  Assignments may be interchanged. 
Several halogenated indoles bearing a N,N,N-trimethyltryptophane betaine moiety including di- and 
tri-iodo as well as both chlorine and iodine atoms on the indole nucleus have been reported from the 
Caribbean  sponge  Plakortis  simplex  [10,13].  The  monobromoderivatives  D-6-  and  L-6- 
bromohypaphorine were previously reported from the Okinawan marine sponge Aplysina sp. and from 
the  sponge  Pachymatisma  johnstoni,  respectively  [11,12]  and  the  dibromoderivative  
5,7-dibromo-L-hypaphorine  was  previously  obtained  by  synthesis  [12].  This  is  the  first  report  of  
5,6-dibromo-L-hypaphorine (9) as a natural product. 
2.3. Biological Activities of Compounds 1–9 
Compounds 1–9 were evaluated for their inhibitory activity against bee venom  PLA2 and their 
antioxidant activity was estimated with the ORAC assay. The results from the in vitro assays are 
presented in Table 2. In addition, their cytotoxicity against the human pharyngeal carcinoma cell line 
was also determined.  
Dibromoindoles 5–9 exhibited the strongest inhibitory activity against bee venom PLA2, with 9 
being identified as the most efficient PLA2 inhibitor of the series albeit with a weak IC50 value of  
0.2 mM.  Mar. Drugs 2011, 9                       
 
 
883 
Table 2. Biological activities of compounds 1–9. 
Compound  PLA2
a  ORAC FL
b 
(1H-Indol-3-yl)oxoacetamide (1)  1.17 ±  0.05  nt 
(1H-Indol-3-yl)oxoacetic acid methyl ester (2)  1.11 ±  0.33  nt 
6-Bromoindole-3-carbaldehyde (3)  1.27 ±  0.06  nt 
Aureol (4)  0.46 ±  0.02  0.29 ±  0.03 
5,6-Dibromotryptamine (5)  0.62 ±  0.01  nt 
N-Methyl-5,6-dibromotryptamine (6)    0.33 ±  0.03  nt 
N,N-Dimethyl-5,6-dibromotryptamine (7)  0.77 ±  0.05  0.06 ±  0.01 
5,6-Dibromoabrine (8)  0.30 ±  0.01  0.07 ±  0.01 
5,6-Dibromo-L-hypaphorine (9)  0.20 ±  0.01  0.22 ±  0.04 
a  IC50  values  (mM  ±   SEM;  n  =  2)  on  bee  venom  PLA2.  Manoalide  (positive  control)  
IC50 0.5 ±  0.05 μM. 
b ORAC values are expressed as relative Trolox equivalent. Fluorescein (FL). 
Relative ORAC value = [(AUC product − AUC blank)/(AUC Trolox − AUC blank)] ×  (molarity 
Trolox/molarity  product),  (n  =  3).  Molarity  in  µ M.  AUC:  Area  Under  the  Curve.  
AUC blank = AUC obtained for the control FL + AAPH. Ascorbic acid (positive control) ORACFL 
0.95 ±  0.02; nt: not tested. 
Figure  3.  Fluorescein  fluorescence  decay  curve  induced  by  AAPH  in  the  presence  of 
Trolox or compounds 4, 7–9.  
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Compounds 4 and 7–9 displayed a positive antioxidant activity as first observed in the qualitative 
DPPH assay. Their antioxidant capacity was quantified in the ORAC assay measuring the loss of 
fluorescence  of  fluorescein  (FL)  in  presence  of  the  oxidative  species  AAPH  (2,2’-azobis(2-
amidinopropane  dihydrochloride))  and  using  Trolox
®  (6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid), a water-soluble analogue of vitamin E, as an anti-oxidant standard against which all 
the compounds were compared. Compounds 4 and 9 exhibited the strongest antioxidant effect with a 
relative ORAC value of 0.29 and 0.22, respectively, as compared with Trolox which had value of 1. 
Figure 3 shows the FL fluorescent decay curves of the four derivatives (4, 7–9) tested at different 
concentrations  in  order  to  obtain  a  profile  similar  to  Trolox.  Compounds  7  and  8  were  the  least 
effective antioxidants. Compound 9 was 4-fold less active than Trolox, displaying a similar curve at Mar. Drugs 2011, 9                       
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24.2 µM, whilst compound 4 demonstrated a similar curve to Trolox at 15.5 µM, revealing it to be  
3-fold less active than Trolox. 
None of the isolated compounds demonstrated any cytotoxicity towards KB cells at 10
−4 M except 4 
(IC50 5 µM), already known for its antitumor activity [6,9].  
3. Experimental Section  
3.1. General Experimental Procedures 
Optical rotations were recorded on a Perkin Elmer 341 polarimeter. UV spectra were recorded on a 
UVIKON 930 spectrometer and IR spectra were recorded on a FT-IR Shimadzu 8400 S spectrometer. 
NMR spectra were obtained on a Bruker AVANCE 400 spectrometer. HSQC and HMBC experiments 
were acquired at 400.13 MHz using a 
1H-
13C Dual probehead. HMBC spectra were optimized for 7 Hz 
coupling. Mass spectra were recorded on an API Q-STAR PULSAR I of Applied Biosystem. HPLC 
were performed with an Alliance apparatus (model 2695, Waters) equipped with a photodiode array 
detector (model 2998, Waters), an evaporative light-scattering detector (model Sedex 80, Sedere) and 
the software Empower. HPLC solvents were purchased from Carlo-Erba. 
3.2. Animal Material 
Specimens  of  Rhopaloeides  odorabile  (class  Demospongiae,  order  Dictyoceratida,  family 
Spongiidae) and Hyrtios sp. (class Demospongiae, order Dictyoceratida, family Thorectidae) were 
collected from Solomon (8°58.968’S, 159°21.953’E) and Fiji islands (16° 13.950’S, 179° 01.900’E), 
respectively. Samples were identified by John Hooper (Queensland Museum, Brisbane). A voucher 
specimen is available for each under the accession numbers G322727 (Rhopaloeides odorabile R3101) 
and G324650 (Hyrtios sp. R3268).  
3.3. Extraction and Isolation  
Lyophilized sponge sample Rhopaloeides odorabile (20 g) was extracted with CH2Cl2 (5 ×  200 mL, 
sonicated each time for 15 min) at room temperature. The five extracts were filtered, combined and 
concentrated under reduced pressure to yield 4 g of CH2Cl2 extract which was chromatographed on a 
silica gel (Merck) column using an initial gradient of cyclohexane/ethyl acetate from 80/20 to 60/40 
followed by a second gradient of CH2Cl2/acetone from 80/20 to 60/40. The 80/20 CH2Cl2/acetone 
fraction (98 mg) exhibited anti-PLA2 activity and was submitted to semi-preparative reversed-phase 
HPLC column chromatography (Interchim, Uptisphere C18 7.8 ×  250 mm) and eluted with increasing 
amounts of MeOH in H2O (flow rate: 3 mL/min, wavelength: 254 nm) through a linear gradient (10% 
to 100% of MeOH) for 35 min and afforded three compounds 1–3 (1: 20 min MeOH/H2O 60/40,  
2: 24 min MeOH/ H2O 70/30, and 3: 27 min MeOH/H2O 80/20 with amounts of 2.6, 1.0 and 1.1 mg, 
respectively).  
Lyophilized sponge sample Hyrtios sp. (16 g) was extracted with MeOH (5 ×  200 mL, sonicated 
each time for 15 min) at room temperature. The five extracts were combined, filtered and concentrated 
under reduced pressure  to  yield  3  g of MeOH extract  which was  treated twice through a solvent 
partition using CH2Cl2 (150 mL) and MeOH/H2O 1:1 (150 mL). After solvent evaporation, 0.9 g of an Mar. Drugs 2011, 9                       
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anti-PLA2 active CH2Cl2 extract and 2.1 g of an anti-PLA2 active MeOH/H2O were obtained. The 
MeOH/H2O extract was chromatographed on a C18 SPE column (Phenomenex) and eluted with H2O, 
H2O/MeOH  2:1,  H2O/MeOH  1:2  and  MeOH  (100  mL  of  each).  The  anti-PLA2  active  fraction 
H2O/MeOH 1:2 (220 mg) was eluted from an Sephadex LH 20 column (GE Healthcare) with MeOH to 
give an anti-PLA2 active yellow fraction (30 mg) which was further submitted to semi-preparative 
reversed-phase  HPLC  column  chromatography  (Interchim,  Uptisphere  C18  7.8  ×   250  mm)  with 
increasing  amounts  of  CH3CN/0.1%  formic  acid  in  H2O/0.1%  formic  acid  as  eluent  (flow  rate:  
3 mL/min, wavelength: 254 nm) through a linear gradient for 30 min. Five peaks between 12 and  
22  min  were  obtained,  and  further  purified  through  an  analytical  reversed-phase  HPLC  column 
(Interchim, Uptisphere C18 4.6 ×  250 mm) with increasing amounts of CH3CN/0.1% formic acid in 
H2O/0.1% formic acid as eluent (flow rate: 1 mL/min, wavelength: 254 nm) through a linear gradient 
for 30 min and yielded pure compounds 5–9 (0.5 mg for 5, 1.4 mg for 6, 1.3 mg for 7, 1.7 mg for 8,  
3.0 mg for 9). An aliquot of the crude CH2Cl2 extract (0.4 g) was chromatographed on a silica gel 
column, using a linear gradient of acetone in CH2Cl2 as eluent. The 50% acetone fraction afforded  
pure 4 (4 mg).  
(1H-Indol-3-yl)oxoacetamide (1). White powder; ESI-MS m/z 189.0677 [M + H]
+ (calcd. 189.0658 for 
C10H9N2O2); spectroscopic data matched those previously published [4]. 
(1H-Indol-3-yl)oxoacetic  acid  methyl  ester  (2).  Yellow  powder;  ESI-MS  m/z  204.0657  [M  +  H]
+ 
(calcd. 204.0660 for C11H10NO3); spectroscopic data matched those previously published [4]. 
6-Bromoindole-3-carbaldehyde (3). Yellow needles; ESI-MS m/z 223/225, m/z 223.9713 [M + H]
+ 
(calcd. 223.9711 for C9H7NO
79Br); spectroscopic data matched those previously published [5]. 
Aureol  (4).  Brown  powder;  ESI-MS  m/z  315.2312  [M  +  H]
+  (calcd.  315.2324  for  C21H31O2); 
spectroscopic data matched those previously published [6]. 
5,6-Dibromotryptamine (5). Light brown powder; ESI-MS m/z 317/319/321, m/z 316.9302 [M + H]
+ 
(m calcd. 316.9289 for C10H11N2
79Br2); spectroscopic data matched those previously published [7]. 
N-Methyl-5,6-dibromotryptamine (6). Light brown powder; ESI-MS m/z 331/333/335, m/z 330.9459 
[M  +  H]
+  (calcd.  330.9439  for  C11H13N2
79Br2);  spectroscopic  data  matched  those  previously  
published [7]. 
N,N-Dimethyl-5,6-dibromotryptamine  (7).  Light  brown  powder;  ESI-MS  m/z  345/347/349,  
m/z  344.9557  [M  +  H]
+  (calcd.  344.9602  for  C12H15N2
79Br2);  spectroscopic  data  matched  those 
previously published [8]. 
5,6-L-Dibromoabrine (8). Light brown powder; []
20
D +17 (c 0.05, MeOH-1 N HCl, 8:2) (lit.[9] +44  
(c  0.05,  1  N  HCl));  ESI-MS  m/z  375/377/379,  m/z  374.9361  [M  +  H]
+  (calcd.  374.9338  for 
C12H13N2O2
79Br2); spectroscopic data matched those previously published [9]. 
5,6-Dibromo-L-hypaphorine  (9).  Pale  yellow  oil;  []
20
D  +28  (c  0.06,  MeOH–1  N  HCl,  8:2);  UV 
(EtOH) λmax (log ) 210 (11,700), 230 (20,645), 294 (2,903) nm; IR (dry film) νmax 3402, 2924, 1597, 
1357 cm
-1; For 
1H and 
13C NMR data, see Table 1; ESI-MS m/z 403/405/407, m/z 402.9667 [M + H]
+ 
(calcd 402.9651 for C14H17N2O2
79Br2). Mar. Drugs 2011, 9                       
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3.4. PLA2 Inhibition Assay 
Bioassay guided fractionation was based on a colorimetric bioassay [14]. Assays were performed in 
duplicate in 96 well plates and read on a CERES 900 spectrophotometer. Extracts (250 µg) or fractions 
(100 µg) dissolved in 10 µL of DMSO were incubated with 2 µL of a PLA2 solution (1 mg/mL in 
DMSO) from Apis mellifera bee venom (Sigma) for 1 hr at 25 ° C. Then 198 µL of the substrate 
solution  L--lecithin  (Sigma)  3.5  mM  containing  Triton  X-100  (7  mM),  NaCl  (100  mM),  
CaCl2 (10 mM) and red phenol (0.055 mM) as colorimetric indicator, at pH 7.6 were added and the 
absorbance  at  550  nm  read  at  time  0  and  5  min.  Percent  inhibition  of  the  enzyme  activity  was 
determined  by  comparison  with  a  control  without  drug.  Manoalide  (Aldrich)  was  used  as  a  
positive control.  
3.5. Antioxidant Assays 
Qualitative  DPPH  screening:  The  potential  antioxidant  activity  of  crude  extracts  and  pure 
compounds were screening using the scavenging activity of the DPPH (Sigma) free radicals. Active 
extracts were visualized by spraying a purple DPPH solution (2 mg/mL in MeOH) on a Tlc plate 
(Merck, Silica gel 60 F254), where compounds have been deposited. Immediate discoloration of DPPH 
around tested samples reveals their antioxidant activity. 
Quantitative  ORAC  assay:  The  antioxidant  activity  of  pure  compounds  was  assessed  with  the 
ORAC  assay.  The  ORAC  assay  is  a  kinetic  assay  measuring  the  decrease  in  fluorescence  of 
fluorescein  (FL)  (Sigma)  by  adding  the  oxidative  species  AAPH  (Aldrich,  2.2’-azobis(2-
amidinopropane  dihydrochloride).  Thus,  antioxidant  protection  of  compounds  was  evaluated  over 
time. The antioxidant Trolox (Aldrich, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) was 
used as a positive control delaying the loss of FL fluorescence in a dose dependent manner [15,16]. 
The antioxidant activity is normalized to equivalent Trolox units to quantify the antioxidant activity of 
each  compound.  The  assay  was  performed  with  a  spectrofluorimeter  Berthold  Mithras  LB  940. 
Reaction mixtures containing 25 µL of different 2-fold dilutions of pure compounds (dissolved in 
phosphate buffer 75 mM, pH 7.4 containing 5% DMSO) or Trolox (200 µM–12.5 µM) and 150 µL of 
FL solution (10 nM in phosphate buffer) were distributed in 96 well  microplates in triplicate and 
incubated at 37° C for 15 min. Fluorescence was measured (Ex. 485 nm, Em. 520 nm) every 90 sec to 
determine  the  background  signal.  After  3  cycles  of  measurement,  25  µL  of  an  AAPH  solution  
(240 mM in phosphate buffer) was added via an automated injector and 60 fluorescence measurements 
were taken over a 90 min time period. The final relative ORAC values for tested compounds were 
calculated  by  using  a  regression  equation  and  were  expressed  as  Trolox  equivalents  according  to  
Ou et al. [16]. Trolox and ascorbic acid (Acros Organics) solutions were used as positive controls and 
FL solution with AAPH as blank. 
3.6. Cytotoxicity Assay 
The  human  KB  cell  line  was  obtained  from  ECACC  (Salisbury,  UK)  and  grown  in  D-MEM 
medium  supplemented  with  10%  fetal  calf  serum  (Invitrogen),  in  the  presence  of  penicillin, 
streptomycin and fungizone in a 75 cm²  flask under 5% CO2. Cells were plated in 96-well tissue Mar. Drugs 2011, 9                       
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culture microplates at a density of 650 cells/well in 200 µL medium and treated 24 hrs later with 
compounds dissolved in DMSO using a Biomek 3000 automate (Beckman-Coulter). Controls received 
the same volume of DMSO (1% final  volume). After 72  hrs  exposure MTS reagent  (Celltiter 96 
Aqueous One solution, Promega) was added and incubated for 3 hrs at 37° C: the absorbance was 
monitored at 490 nm and results expressed as the inhibition of cell proliferation calculated as the ratio 
[(1  −  (OD490  treated/OD490  control))  ×   100].  For  IC50  determinations  (50%  inhibition  of  cell 
proliferation)  experiments  were  performed  with  compound  concentrations  ranging  from  1  µM  to  
100 µM in duplicate. 
4. Conclusions  
In conclusion, our search for new inhibitors of PLA2 and/or antioxidant natural products has led to 
the  investigation  of  specimens  of  the  South  Pacific  marine  sponges  Rhopaloeides  odorabile  and 
Hyrtios  sp.  Eight  indole  derivatives  including  the  new  5,6-dibromo-L-hypaphorine  (9),  and  the 
sesquiterpene aureol (4) were isolated and their chemical structures were resolved by spectroscopic 
analysis. Evaluation of anti-PLA2 and antioxidant activities of the series led to the identification of 
both 4 and 9 as potential antioxidant compounds. In contrast to 4, the new derivative 9 did not show 
any cytotoxic activity towards the human KB cancer cell line. Consequently, 9 could be promising in 
cosmetics and/or in pharmaceutics due to its anti-inflammatory and antioxidant potentials. 
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